Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

The partnership will produce the first ever British Society of Echocardiography National review of Stress Echocardiography Practice (BSE N-STEP).

Echocardiogram photo

The programme builds on the CCRF’S EVAREST research programme, which has established a vast hospital network of academic stress echocardiography centres across the UK, generating a database of 8000 patients. The BSE N-STEP has been created based on this experience, and aims to continue to recruit patients referred for stress echocardiograms across the country. The results will help better understand how protocols are used among different Trusts and the resources involved, as well as the clinical pathway and outcome of patients. Findings from the study should generate important insights into standards of stress echocardiography clinical practice across the NHS.

The BSE N-STEP committee Chair, Dr Dan Augustine, said “This partnership presents a valuable opportunity to review how stress echocardiography is being delivered in real world clinical practice in the UK and allows us to build a national picture of our stress echo use. Information on all forms of stress echo will be captured including assessments for ischaemia, valve disease and viability. From the data it will be possible to analyse protocols; outcomes and cost effectiveness of stress echocardiography within the NHS to promote best practice”.

Professor Paul Leeson, Principal Investigator of the EVAREST research programme, commented: ‘We are delighted to be able to bring together the EVAREST Investigators across the country with the British Society of Echocardiography to facilitate this exciting initiative.

The project will be the first ever national review of the performance of an advanced echocardiography imaging modality within the NHS.
- Professor Paul Leeson

A joint committee will oversee the project including both BSE members Dr Daniel Augustine, Ms Maria Paton, Dr David Oxborough, Mr Shaun Robinson, Mr Keith Pearce and Professor Mark Monaghan alongside Professor Paul Leeson, Dr Elena Benedetto and Cristiana Monteiro, from the University of Oxford.

 If your department is interested in taking part on this project, please email us

Similar stories

Travels with Vignesh

CRM General

Vignesh Murugesan, a Postdoctoral Researcher in Department of Physiology, Anatomy & Genetics (DPAG), describes how he found his way from the large metropolitan town of Chennai in India to studying regenerative medicine here in Oxford, via an 8 year stint in Sweden.

Genetic breakthrough to target care for deadly heart condition

CRE Research

Professor Watkins and his team have found a new type of genetic change in the DNA of people with hypertrophic cardiomyopathy (HCM) - a silent killer amongst families that can cause sudden death in young people due to the thickening of the heart muscle.

Earliest origins of the forming heart identified

CRE Research

The earliest known progenitor of the outermost layer of the heart has been characterised for the first time and linked to the development of other critical cell types in the developing heart in a new paper from the Srinivas group led by BHF Immediate Fellow Dr Richard Tyser.

Professor Sir Rory Collins awarded the MRC Millennium Medal 2020

CRE Research

Professor Sir Rory Collins, Head of the Nuffield Department of Population Health, and Principal Investigator and Chief Executive of UK Biobank, has been awarded the Medical Research Council (MRC) Millennium Medal 2020, the MRC’s most prestigious personal award.

New MRI technique could detect early signs of heart failure in cancer patients following chemotherapy

CRE Publication Research

New research led by Oxford BHF CRE Intermediate Transition Fellow Dr Kerstin Timm shows that a recently developed imaging technique pioneered by the Tyler Group can detect early metabolic changes in the heart caused by a commonly used chemotherapy drug, which is known to increase risk of heart failure in cancer survivors.